ES2523864T3 - Pirimidinas antiinfecciosas y usos de las mismas - Google Patents
Pirimidinas antiinfecciosas y usos de las mismas Download PDFInfo
- Publication number
- ES2523864T3 ES2523864T3 ES11171399.6T ES11171399T ES2523864T3 ES 2523864 T3 ES2523864 T3 ES 2523864T3 ES 11171399 T ES11171399 T ES 11171399T ES 2523864 T3 ES2523864 T3 ES 2523864T3
- Authority
- ES
- Spain
- Prior art keywords
- och3
- compound
- butyl
- infective
- pyrimidines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002924 anti-infective effect Effects 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- -1 3-tert-butyl-5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -yl) -2-methoxyphenyl Chemical group 0.000 abstract description 12
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 abstract 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 43
- 150000001875 compounds Chemical class 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- YNFBMDWHEHETJW-UHFFFAOYSA-N 2-pyridin-2-yl-1h-benzimidazole Chemical compound N1=CC=CC=C1C1=NC2=CC=CC=C2N1 YNFBMDWHEHETJW-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Abstract
Una forma cristalina de N-(6-(3-terc-butil-5-(2,4-dioxo-3,4-dihidropirimidin-1(2H)-il)-2-metoxifenil)naftalen- 2-il)metanosulfonamida o una forma cristalina de una sal de N-(6-(3-terc-butil-5-(2,4-dioxo- 3,4-dihidropirimidin-1(2H)-il)-2-metoxifenil)naftalen-2-il)metanosulfonamida.
Description
E11171399
13-11-2014
TABLA 1
- compuesto
- R6
- anillo/estructura anular
- sustituyente(s)
- IA-L0-2.1
- benzimidazol-2-ilo -5-N(H)S(O)2CH3
- IA-L0-2.2
- benzotiazol-2-ilo -6-N(H)S(O)2CH3
- IA-L0-2.3
- benzotiazol-2-ilo --
- IA-L0-2.4
- benzotiazol-2-ilo -5-N(H)S(O)2CH3
- IA-L0-2.5
- benzoxazol-2-ilo -6-N(H)S(O)2CH3
- IA-L0-2.6
- benzoxazol-2-ilo -6-NO2
- IA-L0-2.7
- benzoxazol-2-ilo -5-NO2
- IA-L0-2.8
- benzoxazol-2-ilo -5-N(H)S(O)2CH3
- IA-L0-2.9
- naftalen-2-ilo -6-N(H)S(O)2CH3
- IA-L0-2.10
- benzimidazol-2-ilo -5-N[S(O)2CH3]2
TABLA 2
- compuesto
- R4 R5 sustituyente(s)
- IB-L0-2.1
- -C(CH3)3 -OCH3 -H -H
- IB-L0-2.2
- -C(CH3)3 -OCH3 -OCH3
- IB-L0-2.3
- -C(CH3)3 -OCH3 -N(H)S(O)2CH3
- IB-L0-2.8
- -C(CH3)3 -H -N(H)S(O)2CH3
- IB-L0-2.14
- -C(CH3)3 -Cl -N(H)S(O)2CH3
- IB-L0-2.23
- -C(CH3)3 -OC(H)2CH3 -N(H)S(O)2CH3
- IB-L0-2.52
- -C(CH3)2C(H)2C(H)3 -OCH3 -N(H)S(O)2CH3
- IB-L0-2.53
- -OCH3 -N(H)S(O)2CH3
- IB-L0.2.54
- -C(CH3)2C(H)2OH -OCH3 -N(H)S(O)2CH3
- IB-L0-2.56
- -CF3 -OCH3 -N(H)S(O)2CH3
- IB-L0-2.57
- -I -OCH3 -N(H)S(O)2CH3
- IB-L0-2.58
- -OCH3 -N(H)S(O)2CH3
- IB-L0-2.59
- furan-2-ilo -OCH3 -N(H)S(O)2CH3
- IB-L0-2.60
- -C(F)2CF3 -OCH3 -N(H)S(O)2CH3
- IB-L0-2.61
- -OCH3 -N(H)S(O)2CH3
- IB-L0-2.64
- furan-3-ilo -OCH3 -N(H)S(O)2CH3
- IB-L0-2.66
- -C(CH3)2C(H)2OCH3 -OCH3 -N(H)S(O)2CH3
- IB-L0-2.68
- -S(O)2CH3 -OCH3 -N(H)S(O)2CH3
- IB-L0-2.69
- -Br -OCH3 -N(H)S(O)2CH3
- IB-L0-2.70
- -C(CH3)2C(O)OCH3 -OCH3 -N(H)S(O)2CH3
34
E11171399
13-11-2014
- compuesto
- R4 R5 sustituyente(s)
- IB-L0-2.71
- fenilo -OCH3 -N(H)S(O)2CH3
- IB-L0-2.72
- -C(O)OCH3 -OCH3 -N(H)S(O)2CH3
- IB-L0-2.73
- -OCH3 -N(H)S(O)2CH3
- IB-L0-2.74
- -OCH3 -N(H)S(O)2CH3
- IB-L0-2.75
- -N(H)S(O)2CH3 -OCH3 -N(H)S(O)2CH3
- IB-L0-2.76
- -OCH3 -N(R)S(O)2CH3
- IB-L0-2.77
- -C(CH3)2C(O)OH -OCH3 -N(H)S(O)2CH3
- IB-L0-2.78
- -C≡CSi(CH3)3 -OCH3 -N(H)S(O)2CH3
TABLA 3
- compuesto
- R5 sustituyente(s)
- IB-L0-2.4
- -OCH3 =NN(H)S(O)2CH3
- IB-L0-2.7
- -H =NN(H)S(O)2CH3
- IB-L0-2.9
- -OCH3 (S) -C(H)2N(H)S(O)2CH3
- IB-L0-2.10
- -OCH3 (R) -F y -C(H)2N(H)S(O)2CH3
- IB-L0-2.12
- -OCH3 -F y -C(H)2N(H)S(O)2CH3
- IB-L0-2.15
- -OCH3 (R) -C(H)2N(H)S(O)2CH3
- IB-L0-2.17
- -OCH3 -C(H)2N(H)S(O)2CH3
- IB-L0-2.20
- -OCH3 (S) -F y -C(H)2N(H)S(O)2CH3
- IB-L0-2.22
- -OCH3 (S) -C(CH3)2N(H)S(O)2CH3
- IB-L0-2.24
- -OCH3 =NN(H)C(O)OCH3
- IB-L0-2.25
- -OCH3 -CH3 y -C(H)2N(H)S(O)2CH3
- IB-L0-2.29
- -OCH3 -C(CH3)2N(H)S(O)2CH3
- IB-L0-2.31
- -OCH3 -N(H)N(H)S(O)2CH3
- IB-L0-2.34
- -OCH3 -C(O)N(H)S(O)2CH3
- IB-L0-2.36
- -OCH3 -OH
- IB-L0-2.37
- -OCH3 (R) -C(CH3)2N(H)S(O)2CH3
- IB-L0-2.44
- -OCH3 -N(H)S(O)2CH3
- IB-L0-2.50
- -OCH3 =O
35
E11171399
13-11-2014
ESQUEMA 5
5 El fenol (20-1), donde R4 es distinto de amino, se trata con una fuente de haluro electrófilo, tal como, por ejemplo, monocloruro de yodo para proporcionar el compuesto dihalogenado (20-2), donde X1 y X2 son independientemente bromo o yodo. El compuesto (20-2) se transforma en el compuesto (20-3) por medio de reacción de un agente alquilante tal como, por ejemplo, sulfato de metilo con una base tal como, por ejemplo, carbonato de potasio en acetona a reflujo. Alternativamente, yoduro de metilo en presencia de una base tal como, por ejemplo, t-butóxido de
10 potasio en un disolvente tal como, por ejemplo, tetrahidrofurano, o dimetilformamida también proporciona el compuesto (20-3). En otra alternativa más, el compuesto (20-2) se puede metilar con (trimetilsilil)diazometano en un disolvente tal como, por ejemplo, t-butil metil éter. El compuesto (20-3) se puede hacer reaccionar con uracilo, ligando (20-4), yoduro de cobre (I), y fosfato de potasio en dimetilsulfóxido de aproximadamente 40 °C a aproximadamente 100 °C para suministrar el compuesto (20-5).
15 Por ejemplo, cuando en compuesto (20-3), R4es terc-butilo, X1 es yodo, y X2 es yodo o bromo, compuesto (20-3) can be se agitó con uracilo y compuesto (20-4) en presencia de CuI y K2PO4 en DMSO durante aproximadamente 15 a aproximadamente 24 h a aproximadamente 60 °C para suministrar el compuesto (20-5). Las alternativas al ligando (20-4) para elaborar (20-5) son 8-hidroxiquinolina y 2-(2-piridil)-benzimidazol.
20
El compuesto (25-1) se puede bromar por medio de tratamiento con, por ejemplo, hidrobromuro perbromuro de
25 piridinio en un disolvente tal como, por ejemplo, ácido acético a temperatura ambiente o casi a temperatura ambiente a lo largo de un período de aproximadamente 1 a aproximadamente 8 h para producir el compuesto (25-2). El grupo amino del compuesto (25-2) se puede eliminar mediante exposición a nitrito de t-butilo en un disolvente tal como, por ejemplo, dimetilformamida a una temperatura inicialmente a temperatura ambiente y a continuación aumentar al intervalo de aproximadamente 50 a aproximadamente 65 °C para producir el compuesto (25-3). Se pueden añadir
30 alícuotas adicionales de nitrito de t-butilo a temperatura ambiente seguido de calentamiento hasta que la transformación es completa. El compuesto (25-3) se puede reducir al compuesto (25-4), por ejemplo, mediante tratamiento con hierro y cloruro de amonio.
56
Tabla CE50
- compuesto
- 1a 1b compuesto 1a 1b
- IA-LO-2,1
- D D
- IA-LO-2,2
- C B IA-LO-2,3 C C
- IA-LO-2,4
- D C IA-LO-2,5 D D
- IA-LO-2,6
- D D IA-LO-2,7 D C
- IA-LO-2,8
- C B IA-LO-2,9 A A
- IA-L0-2,10
- ND ND IB-L0-2.1 D C
- IB-L0-2.2
- D D IB-L0-2.3 A A
- IB-L0-2.4
- ND A IB-L0-2.5 B A
- IB-L0-2.6
- C B IB-L0-2.7 C B
- IB-L0-2.8
- ND B IB-L0-2.9 A A
- IB-L0-2.10
- A A IB-L0-2.11 B A
- IB-L0-2.12
- B A IB-L0-2.13 B A
- IB-L0-2.14
- C B IB-L0-2.15 C B
- IB-L0-2.16
- C A IB-L0-2.17 B A
- IB-L0-2.18
- C B IB-L0-2.19 B B
- IB-L0-2.20
- C B IB-L0-2.21 C B
- IB-L0-2.22
- C B IB-L0-2.23 C B
- IB-L0-2.24
- B B IB-L0-2.25 C B
- IB-L0-2.26
- D C IB-L0-2.27 C B
- IB-L0-2.28
- D C IB-L0-2.29 C B
- IB-L0-2.30
- C B IB-L0-2.31 C B
- IB-L0-2.32
- C B IB-LO-233 C C
- IB-L0-2.34
- D C IB-L0-2.35 D C
- IB-L0-2.36
- C B IB-L0-2.37 D C
- IB-LO-238
- D D IB-L0-2.39 D C
- IB-L0-2.40
- D C IB-L0-2.41 C C
- IB-L0-2.42
- C C IB-L0-2.43 D C
- IB-L0-2.44
- D D IB-L0-2.45 D C
- IB-L0-2.46
- ND ND IB-L0-2.47 ND ND
- IB-L0-2.48
- ND ND IB-L0-2.49 ND ND
- IB-L0-2.50
- C C IB-L0-2.51 B A
- IB-L0-2.52
- B A IB-L0-2.53 B B
- IB-L0-2.54
- B B IB-L0-2.55 B A
- IB-L0-2.56
- C A IB-L0-2.57 C B
- IB-L0-2.58
- B A IB-L0-2.59 C B
- IB-L0-2.60
- C B IB-L0-2.61 C B
- IB-L0-2.62
- C B IB-L0-2.63 C B
- IB-L0-2.64
- C A IB-L0-2.65 C B
- IB-L0-2.66
- C B IB-L0-2.67 C B
- IB-L0-2.68
- D C IB-L0-2.69 C B
- IB-L0-2.70
- D C IB-L0-2.71 C B
- IB-L0-2.72
- D C IB-L0-2.73 C C
- IB-L0-2.74
- D C IB-L0-2.75 D D
- IB-L0-2.76
- ND ND IB-L0-2.77 ND ND
- IB-L0-2.78
- ND ND IB-L0-2.79 C C
131
Claims (1)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6 imagen7
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97288107P | 2007-09-17 | 2007-09-17 | |
| US972881P | 2007-09-17 | ||
| US9679208P | 2008-09-13 | 2008-09-13 | |
| US96792P | 2008-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2523864T3 true ES2523864T3 (es) | 2014-12-02 |
Family
ID=40308557
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12182277.9T Active ES2592961T3 (es) | 2007-09-17 | 2008-09-17 | Pirimidinas antiinfecciosas y usos de las mismas |
| ES08832330T Active ES2368879T3 (es) | 2007-09-17 | 2008-09-17 | Pirimidinas antiinfecciosas y usos de las mismas. |
| ES11171399.6T Active ES2523864T3 (es) | 2007-09-17 | 2008-09-17 | Pirimidinas antiinfecciosas y usos de las mismas |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12182277.9T Active ES2592961T3 (es) | 2007-09-17 | 2008-09-17 | Pirimidinas antiinfecciosas y usos de las mismas |
| ES08832330T Active ES2368879T3 (es) | 2007-09-17 | 2008-09-17 | Pirimidinas antiinfecciosas y usos de las mismas. |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8188104B2 (es) |
| EP (3) | EP2368882B1 (es) |
| JP (3) | JP5734655B2 (es) |
| CN (4) | CN104628655A (es) |
| AT (1) | ATE519746T1 (es) |
| CA (2) | CA2849420C (es) |
| CY (3) | CY1115514T1 (es) |
| DK (3) | DK2639226T3 (es) |
| ES (3) | ES2592961T3 (es) |
| HK (2) | HK1148273A1 (es) |
| HR (2) | HRP20110809T1 (es) |
| HU (1) | HUS1500013I1 (es) |
| LT (1) | LTC2203431I2 (es) |
| LU (1) | LU92666I2 (es) |
| MX (1) | MX2010002902A (es) |
| NL (1) | NL300729I2 (es) |
| NO (1) | NO2015011I1 (es) |
| PL (3) | PL2203431T3 (es) |
| PT (3) | PT2203431E (es) |
| RU (2) | RU2539570C2 (es) |
| SI (2) | SI2203431T1 (es) |
| WO (1) | WO2009039134A1 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2849420C (en) * | 2007-09-17 | 2016-07-12 | Abbvie Bahamas Ltd. | Anti-infective pyrimidines and uses thereof |
| TWI534137B (zh) | 2007-09-17 | 2016-05-21 | 艾伯維巴哈馬有限公司 | 抗感染劑及其用途 |
| US8178548B2 (en) | 2007-09-17 | 2012-05-15 | Abbott Laboratories | Anti-infective agents and uses thereof |
| KR20110033291A (ko) * | 2008-07-23 | 2011-03-30 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
| CA2736472A1 (en) | 2008-09-26 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyrine or pyrazine derivatives for treating hcv |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| MX2011010047A (es) * | 2009-03-25 | 2011-10-11 | Abbott Lab | Compuestos antivirales y usos de los mismos. |
| SG175774A1 (en) | 2009-04-25 | 2011-12-29 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| TWI428332B (zh) | 2009-06-09 | 2014-03-01 | Hoffmann La Roche | 雜環抗病毒化合物 |
| MX2011012541A (es) | 2009-06-24 | 2012-08-03 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
| JP2013505218A (ja) | 2009-09-21 | 2013-02-14 | エフ．ホフマン−ラ ロシュ アーゲー | 複素環式抗ウイルス化合物 |
| AU2010297557C1 (en) | 2009-09-25 | 2017-04-06 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| CA2778206A1 (en) * | 2009-11-21 | 2011-05-26 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CN102652134A (zh) * | 2009-12-14 | 2012-08-29 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| KR20120093428A (ko) * | 2009-12-14 | 2012-08-22 | 메르크 파텐트 게엠베하 | 스핑고신 키나아제 저해제 |
| WO2011106573A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| KR101794020B1 (ko) | 2010-04-19 | 2017-11-06 | 오리존 지노믹스 에스.에이. | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| CA2804827A1 (en) | 2010-07-16 | 2012-01-19 | Shashank Shekhar | Phosphine ligands for catalytic reactions |
| EP2593439B1 (en) | 2010-07-16 | 2016-08-17 | AbbVie Bahamas Ltd. | Process for preparing antiviral compounds |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| NO2598482T3 (es) | 2010-07-29 | 2018-09-01 | ||
| WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体 |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| CN102675092B (zh) * | 2011-03-14 | 2014-11-05 | 江苏中丹药物研究有限公司 | 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| EP4074695A1 (en) | 2011-10-20 | 2022-10-19 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| TW201600087A (zh) * | 2011-10-21 | 2016-01-01 | 艾伯維有限公司 | 治療ｃ型肝炎病毒（ｈｃｖ）的方法 |
| DK2583677T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CA2882624A1 (en) | 2012-08-21 | 2014-02-27 | Shashank Shekhar | Process for preparing antiviral compounds |
| EA032913B1 (ru) * | 2012-10-18 | 2019-08-30 | Эббви Инк. | Препараты производных пиримидиндиона |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| CN106065009B (zh) * | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| EA036086B1 (ru) * | 2016-03-17 | 2020-09-24 | Фмк Корпорейшн | Способ превращения s-энантиомера в его рацемическую форму |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
| WO2017202207A1 (zh) * | 2016-05-27 | 2017-11-30 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的萘环化合物及药物组合物及其应用 |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) * | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| US5084084A (en) | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| AU627906B2 (en) | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| CA2036304C (en) | 1990-02-15 | 2001-04-17 | Takehiko Naka | Pyrimidinedione derivatives, their production and use |
| NL9001075A (es) * | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| ATE357433T1 (de) | 1999-12-06 | 2007-04-15 | Hoffmann La Roche | 4-pyrimidinyl-n-acyl-l-phenylanine |
| IL167957A (en) | 2000-02-04 | 2009-07-20 | Sumitomo Chemical Co | Hydroxypyridine compounds |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| WO2003068162A2 (en) * | 2002-02-14 | 2003-08-21 | Pharmasset Ltd. | Modified fluorinated nucleoside analogues |
| AU2003288198A1 (en) * | 2002-11-28 | 2004-06-18 | Schering Aktiengesellschaft | CHK-,PDK- and AKT-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| KR100589964B1 (ko) * | 2003-06-13 | 2006-06-19 | 주식회사 엘지생명과학 | Ｃ형 간염 바이러스의 억제제 |
| KR20060054410A (ko) * | 2003-08-01 | 2006-05-22 | 제네랩스 테크놀로지스, 인코포레이티드 | 플라비비리다에에 대한 2고리 이미다졸 유도체 |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| BRPI0511834A (pt) * | 2004-07-14 | 2008-01-08 | Ptc Therapeutics Inc | métodos por tratar hepatite c |
| EP1953147A1 (en) * | 2005-11-21 | 2008-08-06 | Japan Tobacco, Inc. | Heterocyclic compound and medicinal application thereof |
| TWI534137B (zh) * | 2007-09-17 | 2016-05-21 | 艾伯維巴哈馬有限公司 | 抗感染劑及其用途 |
| US8178548B2 (en) | 2007-09-17 | 2012-05-15 | Abbott Laboratories | Anti-infective agents and uses thereof |
| CA2849420C (en) * | 2007-09-17 | 2016-07-12 | Abbvie Bahamas Ltd. | Anti-infective pyrimidines and uses thereof |
| KR20110033291A (ko) | 2008-07-23 | 2011-03-30 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
-
2008
- 2008-09-17 CA CA2849420A patent/CA2849420C/en active Active
- 2008-09-17 PT PT08832330T patent/PT2203431E/pt unknown
- 2008-09-17 PL PL08832330T patent/PL2203431T3/pl unknown
- 2008-09-17 ES ES12182277.9T patent/ES2592961T3/es active Active
- 2008-09-17 CN CN201410659529.4A patent/CN104628655A/zh active Pending
- 2008-09-17 DK DK12182277.9T patent/DK2639226T3/en active
- 2008-09-17 ES ES08832330T patent/ES2368879T3/es active Active
- 2008-09-17 DK DK08832330T patent/DK2203431T3/da active
- 2008-09-17 ES ES11171399.6T patent/ES2523864T3/es active Active
- 2008-09-17 EP EP20110171399 patent/EP2368882B1/en active Active
- 2008-09-17 SI SI200830433T patent/SI2203431T1/sl unknown
- 2008-09-17 DK DK11171399T patent/DK2368882T3/en active
- 2008-09-17 US US12/212,323 patent/US8188104B2/en active Active
- 2008-09-17 MX MX2010002902A patent/MX2010002902A/es active IP Right Grant
- 2008-09-17 RU RU2010114827/04A patent/RU2539570C2/ru active
- 2008-09-17 AT AT08832330T patent/ATE519746T1/de active
- 2008-09-17 EP EP12182277.9A patent/EP2639226B1/en not_active Not-in-force
- 2008-09-17 WO PCT/US2008/076592 patent/WO2009039134A1/en active Application Filing
- 2008-09-17 CA CA2699986A patent/CA2699986C/en not_active Expired - Fee Related
- 2008-09-17 CN CN201410657922.XA patent/CN104628654A/zh active Pending
- 2008-09-17 CN CN200880113534.8A patent/CN101842360B/zh active Active
- 2008-09-17 EP EP20080832330 patent/EP2203431B1/en active Active
- 2008-09-17 PT PT11171399T patent/PT2368882E/pt unknown
- 2008-09-17 SI SI200831329T patent/SI2368882T1/sl unknown
- 2008-09-17 RU RU2014147354/04A patent/RU2014147354A/ru not_active Application Discontinuation
- 2008-09-17 JP JP2010525103A patent/JP5734655B2/ja active Active
- 2008-09-17 CN CN201210167588.0A patent/CN102746240B/zh not_active Expired - Fee Related
- 2008-09-17 PT PT121822779T patent/PT2639226T/pt unknown
- 2008-09-17 PL PL11171399T patent/PL2368882T3/pl unknown
- 2008-09-17 PL PL12182277T patent/PL2639226T3/pl unknown
-
2011
- 2011-03-08 HK HK11102295.5A patent/HK1148273A1/xx unknown
- 2011-10-03 HK HK11110421.5A patent/HK1156033A1/xx not_active IP Right Cessation
- 2011-11-02 HR HR20110809T patent/HRP20110809T1/hr unknown
- 2011-11-03 CY CY20111101065T patent/CY1115514T1/el unknown
-
2012
- 2012-04-20 US US13/451,889 patent/US8501238B2/en active Active
- 2012-10-04 JP JP2012221886A patent/JP5931683B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-15 US US13/838,223 patent/US9139536B2/en active Active
-
2014
- 2014-11-12 HR HRP20141102 patent/HRP20141102T1/hr unknown
- 2014-11-12 CY CY20141100943T patent/CY1115893T1/el unknown
-
2015
- 2015-02-25 LU LU92666C patent/LU92666I2/xx unknown
- 2015-03-04 LT LTPA2015013C patent/LTC2203431I2/lt unknown
- 2015-03-17 HU HUS1500013C patent/HUS1500013I1/hu unknown
- 2015-03-26 CY CY2015013C patent/CY2015013I1/el unknown
- 2015-04-08 NL NL300729C patent/NL300729I2/nl unknown
- 2015-04-14 JP JP2015082240A patent/JP2015187106A/ja active Pending
- 2015-04-22 NO NO2015011C patent/NO2015011I1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2523864T3 (es) | Pirimidinas antiinfecciosas y usos de las mismas | |
| HRP20200673T1 (hr) | Makrociklički inhibitori mcl1 za liječenje raka | |
| HRP20201420T1 (hr) | Derivati žučne kiseline kao agonisti fxr/tgr5 | |
| AR067355A1 (es) | Procesos para la preparacion de pirazoles | |
| ES2512591T3 (es) | Método de producción de 2'-desoxi-5-azacitidina (decitabina) | |
| RU2009122692A (ru) | Способ получения иматиниба и его промежуточных соединений | |
| HRP20050190B1 (hr) | Derivati dioksan-2-alkil karbamata, metoda njihove pripreme i primjena istih u terapeutske svrhe | |
| KR850008668A (ko) | 프탈라지논 유도체의 제조방법 | |
| PT100366A (pt) | Derivados de tiazolidina-diona, e processo para a sua preparacao e composicoes farmaceuticas que os contem | |
| CN103664963B (zh) | 一种喹唑啉酮并吲唑衍生物的合成方法 | |
| RU2005105585A (ru) | Производные пиразола и способ их получения | |
| PE20060600A1 (es) | Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa | |
| RS53679B1 (en) | FURAZANOBENZIMIDAZOLES AS PROGRAMS FOR THE TREATMENT OF NEOPLASTIC OR AUTOIMMUNE DISEASES | |
| PE20090960A1 (es) | Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas | |
| PE20081472A1 (es) | Compuestos de pirazolina | |
| RU2013137753A (ru) | Твердые формы ингибитора гиразы (r)-1-этил-3-[5-[2-(1-гидрокси-1-метилэтил)пиримидин-5-ил]-7-(тетрагидрофуран-2-ил)-1н-бензимидазол-2-ил]мочевины | |
| CN104016968A (zh) | 用于Cu（Ⅰ）的配体的N1取代的1,2,3-三唑衍生物及其制备方法和应用 | |
| IL292090B2 (en) | Method for preparing 5-bromo-2-(3-chloro-pyridin-2-yl)-2h-pyralose-3-carboxylic acid | |
| CN103980280A (zh) | 一种酸性条件下合成喹唑啉酮并吲唑衍生物的方法 | |
| US20190276429A1 (en) | 4-(6-(2-(2,4-difluorophenyl)-1.1-difluoro-2-hydroxy-3-(5-mercapto-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation | |
| CY1113031T1 (el) | Παραγωγα ν-αμινοϊμιδαζολιου που αναστελουν ηιv | |
| CO5271645A1 (es) | Nuevos compuestos | |
| Colombo et al. | Stereomeric studies on the oxidation and alkylation of 4-thiazolidinones | |
| ES2597853T3 (es) | Procedimiento para la preparación de ésteres alquílicos de ácido dihaloacetoacético | |
| JP2018536652A5 (es) |